Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

BACKGROUND: Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery. METHOD: Pharmacokinetic data were obtain...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xiaohua, Chen, Xuejun, Kuligowski, Michael E., Liu, Xing, Liu, Xiang, Cimino, Evan, McGee, Ryan, Yeleswaram, Swamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200345/
https://www.ncbi.nlm.nih.gov/pubmed/33982267
http://dx.doi.org/10.1007/s40257-021-00610-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200345/
https://www.ncbi.nlm.nih.gov/pubmed/33982267
http://dx.doi.org/10.1007/s40257-021-00610-x

Ejemplares similares